Clinical Trial

Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to define and compare the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EYP651 at two dose levels and compare it with Vonafexor Acid PK and PD profile, the Part A. In addition, Part B of the trial will assess the Drug-Drug Interactions (DDI) potential with the high dose of EYP651.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-18.
Trial Details
NCT Number NCT07251153
Lead Sponsor Enyo Pharma
Conditions Healthy Adult Male and Female Volunteers
Enrollment 40 participants
Start Date 2025-10-28
Primary Completion 2025-12-18 (estimated)
Study Completion 2026-10-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-27